BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 16360833)

  • 21. In vitro anti-tumor immune response induced by dendritic cells transfected with EBV-LMP2 recombinant adenovirus.
    Pan Y; Zhang J; Zhou L; Zuo J; Zeng Y
    Biochem Biophys Res Commun; 2006 Sep; 347(3):551-7. PubMed ID: 16842756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy for Hodgkin's disease.
    Rooney CM; Bollard C; Huls MH; Gahn B; Gottschalk S; Wagner HJ; Anderson R; Prentice HG; Brenner MK; Heslop HE
    Ann Hematol; 2002; 81 Suppl 2():S39-42. PubMed ID: 12611071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tumor RNA introduction into dendritic cells and Epstein-Barr virus transformed B cells].
    Minami K; Yamaguchi Y; Ohshita A; Kawabuchi Y; Shimizu K; Ohta K; Hihara J; Miyahara E; Toge T
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1813-6. PubMed ID: 14619527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [In vitro induced and expanded Epstein Barr virus-specific cytotoxic T lymphocytes can specifically kill nasopharyngeal carcinoma cells].
    Chen LP; Huang JQ; Zhou TC; Zhang SX; Wang JL
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1431-3. PubMed ID: 18753079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant.
    Regn S; Raffegerst S; Chen X; Schendel D; Kolb HJ; Roskrow M
    Bone Marrow Transplant; 2001 Jan; 27(1):53-64. PubMed ID: 11244438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
    Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
    J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A quantitative assay for Epstein-Barr Virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease.
    Guppy AE; Rawlings E; Madrigal JA; Amlot PL; Barber LD
    Transplantation; 2007 Dec; 84(11):1534-9. PubMed ID: 18091531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of T-cell immunity against Epstein-Barr virus-associated tumors by means of adenovirally transduced dendritic cells.
    Sun H; Yao K; Chen Y; Zhou F
    Chin Med J (Engl); 2004 Oct; 117(10):1558-63. PubMed ID: 15498383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy.
    Sherritt MA; Bharadwaj M; Burrows JM; Morrison LE; Elliott SL; Davis JE; Kear LM; Slaughter RE; Bell SC; Galbraith AJ; Khanna R; Moss DJ
    Transplantation; 2003 May; 75(9):1556-60. PubMed ID: 12792514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide.
    Orentas RJ; Roskopf SJ; Nolan GP; Nishimura MI
    Clin Immunol; 2001 Feb; 98(2):220-8. PubMed ID: 11161978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma.
    Boyle TJ; Berend KR; DiMaio JM; Coles RE; Via DF; Lyerly HK
    Surgery; 1993 Aug; 114(2):218-25; discussion 226. PubMed ID: 8393595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.
    Xu JJ; Yao K; Yu CJ; Chen X; Lu MP; Sun H; Li BZ; Ding CN; Zhou F
    Auris Nasus Larynx; 2006 Dec; 33(4):441-6. PubMed ID: 16934422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined transfection with EBV-specific epitopes and HLA-A2 genes is more effective than separate transfection in promoting CTL lysis against nasopharyngeal carcinoma.
    Ding W; Fong C
    Cell Mol Immunol; 2004 Jun; 1(3):229-34. PubMed ID: 16219173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH; Wolf H; Minarovits J
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.
    Adhikary D; Behrends U; Moosmann A; Witter K; Bornkamm GW; Mautner J
    J Exp Med; 2006 Apr; 203(4):995-1006. PubMed ID: 16549597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro methods for generating highly purified EBV associated tumor antigen-specific T cells by using solid phase T cell selection system for immunotherapy.
    Li J; Mookerjee B; Wagner J; Flomenberg N
    J Immunol Methods; 2007 Dec; 328(1-2):169-81. PubMed ID: 17931649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells.
    Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    Cancer Sci; 2008 Aug; 99(8):1633-42. PubMed ID: 18754877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Establishment and characterization of Epstein-Barr virus-specific human CD4+ T lymphocyte clones.
    Honda S; Takasaki T; Okuno K; Yasutomi M; Kurane I
    Acta Virol; 1998 Nov; 42(5):307-13. PubMed ID: 10358731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mature dendritic cells are superior to immature dendritic cells in expanding antigen-specific naive and memory CD8+ T cells.
    Tomiyama M; Takahara M; Egawa K; Nieda M
    Anticancer Res; 2004; 24(5C):3327-33. PubMed ID: 15515428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.